九源基因去年净利增超15%,减重版司美格鲁肽或明年上半年提交上市申请

澎湃新闻
27 Mar

手握司美格鲁肽生物类似药的九源基因公布港股上市后首份业绩公告。3月26日晚间,杭州九源基因工程股份有限公司(九源基因,2566.HK)公布了上市后首份年度业绩公告,公司2024年总收入为13.69亿元,同比增长6.4%;净利润1.39亿元,同比增长15.7%。九源基因成立于1993年,2024年11月港股上市,业务覆盖骨科、代谢疾病、肿瘤及血液等四大治疗领域,已有9款商业化产品。2024年,生物药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10